Table 2.

Parasitological results and statistical differences between groups four years after doxycycline MDA implementation

	Treatment group
	Doxycycline + ivermectin	Ivermectin only	p-value
Mf prevalence (%) (95% CI)	17% (13%-21%)	27% (19%-35%)	0.014
Mf/mg skin Median (75-95 percentile)	0 (0-3.5)	0 (0.37-5.37)	0.012
Nodule prevalence (%) (95% CI)	19% (15%-23%)	20% (13%-27%)	0.776
Nodules/person Median (75-95 percentile)	0 (0-2)	0 (0-2)	0.720
Mf prevalence in nodule+subjects (%) (95% CI)	34% (23%-46%)	54% (33%-74%)	0.091
Mf/mg skin in nodule+subjects Median (75-95 percentile)	0 (0.71-11.33)	0 (4.00-64.53)	0.032